Abivax présente les dernières avancées de ses activités et ses résultats financiers du premier semestre 2026

Abivax reported a first-half 2026 net loss of €165.9M, widening from €100.8M a year earlier, as R&D spending rose €29.9M to €107.9M to advance obefazimod and prepare for potential commercialization. Cash, equivalents and short-term investments totaled €402.4M at June 30; combined with €767.1M net proceeds from July's public offering, the company expects funding runway through Q4 2029. Abivax also retired its royalty certificates for $90M, reducing future royalty obligations, and is targeting a U.S. NDA filing for obefazimod in ulcerative colitis by year-end 2026.

Analysis

ABVX has removed the near-term financing overhang that normally forces pre-revenue biotech investors to discount an equity raise into every regulatory milestone. The market should now shift from runway valuation toward probability-adjusted peak-sales and launch-execution valuation; that supports a higher floor into the planned filing, but also makes any regulatory or manufacturing deficiency more consequential because the balance-sheet hedge is already reflected. The royalty retirement improves eventual gross-margin capture, although the economic benefit is back-end loaded and should not be valued as near-term EPS accretion.

The immediate catalyst path is limited: senior appointments and half-year accounts are unlikely to alter consensus approval probability. Over the next 1-3 months, UEGW feedback, filing-date precision and any disclosure on label ambitions, payer positioning, and commercial manufacturing readiness matter more than reported operating loss. A CMO transition before filing is a modest governance risk rather than a thesis breaker; the key diligence item is whether the incoming team preserves regulator continuity and whether CMC spending translates into validated commercial supply rather than simply higher fixed costs.

At 6-18 months, ABVX competes for ulcerative-colitis sequencing against entrenched biologics and oral small molecules, including BMY's Zeposia and Takeda's Entyvio franchise, rather than merely for approval. A differentiated safety/efficacy profile could expand use in refractory patients, but crowded treatment algorithms and payer step edits can delay uptake even with approval. Consensus may underweight this launch friction while overreacting to the cash balance: a long runway prevents dilution, not a weaker label, slower formulary access, or an unfavorable safety characterization.

The July equity issuance creates a practical technical constraint: assess the offering price, current trading level and post-deal turnover before chasing strength. If ABVX trades materially below the raise price despite no adverse clinical/regulatory signal, the dislocation is more actionable than this release itself; if it trades above it, the stock likely requires filing acceptance or clearer commercial differentiation to sustain multiple expansion.

Key Decisions for Investors

• Maintain ABVX as a catalyst watch/accumulate-on-weakness position into the expected year-end NDA submission; size modestly until the filing is formally accepted. Add only if shares trade below the July financing reference with stable regulatory guidance, targeting a 15-25% rerating into acceptance; exit on a filing delay, CMC deficiency disclosure, or material safety-label deterioration.
• Do not treat the stated runway as sufficient reason to chase ABVX after a gap-up. Require evidence on commercial batch validation, expected label population and US payer-access assumptions; these are the missing inputs needed to underwrite peak-sales probability and launch-margin assumptions.
• Use BIIB and CRBU only as biotech-risk hedges, not fundamental pairs: neither has a clean ulcerative-colitis operating linkage. For a sector hedge, prefer a broad biotech proxy such as XBI against an ABVX long during binary regulatory windows.
• Set a monitoring trigger for the next update: quantify quarterly cash burn excluding one-off royalty settlement effects. A sustained run-rate materially above management's implied 2029 runway would reintroduce dilution risk and warrants reducing exposure before the Crohn topline catalyst in mid-2027.